これが伏見流!　心房細動の診かた、全力でわかりやすく教えます。

出版社： 羊土社
著者：
発行日： 2017-04-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784758107570
電子書籍版： 2017-04-01 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

心房細動の「どの薬を使うべき？」「既往症・合併症への対処法は？」「周術期管理は？」などよくある悩みにお答えします！実臨床での治療を全力で解説したこれまでにない実践書！すべての臨床医におすすめ！

目次

  • これが伏見流！　心房細動の診かた、全力でわかりやすく教えます。

    ―目次―

    序章 伏見AFレジストリの概要

    第1章 はじまりは心電図
    　1．AF心電図で見るべきポイント
    　2．発作性か？ 慢性か？

    第2章 全身を評価する
    　1．年齢
    　2．高血圧，糖尿病
    　3．腎機能
    　4．冠動脈疾患，PAD
    　5．脳卒中既往
    　6．心不全
    　7．心筋症
    　8．左房
    　9．喫煙，飲酒

    第3章 脳塞栓症を防ぐ
    　1．リスクスコア
    　2．ワーファリン
    　3．DOAC
    　4．抗血小板薬

    第4章 症状を緩和する
    　1．リズムコントロール
    　2．レートコントロール

    第5章 連携して診る
    　1．患者教育
    　2．服薬アドヒアランス
    　3．連携手帳
    　4．処方,服薬管理,服薬指導のポイント
    　5．消化器内視鏡への対応
    　6．外科手術への対応
    　7．急性期脳梗塞治療
    　8. 観察研究での統計解析

    第6章 徹底討論！症例カンファレンス
    　Case1．DOAC 症例,周術期のヘパリン置換どうする?
    　Case2．AF合併の心不全，アブレーションで救えるか?
    　Case3．出血も血栓症もハイリスク患者の
    　　　　　PCI,抗血栓療法どうする?
    　Case4．脳梗塞と大出血をくり返す超ハイリスク症例, どうする?

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 伏見 AFレジストリの概要

P.18 掲載の参考文献
1) Akao M, et al:Current status of clinical background of patients with atrial fibrillation in a community-based survey:the Fushimi AF Registry. J Cardiol, 61:260-266, 2013
 
2) Akao M, et al:Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J, 78:2166-2172, 2014
PubMed
3) Ohsawa M, et al:Rapid increase in estimated number of persons with atrial fibrillation in Japan:an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol, 15:194-196, 2005
PubMed
4) Inoue H, et al:Prevalence of atrial fibrillation in the general population of Japan:an analysis based on periodic health examination. Int J Cardiol, 137:102-107, 2009
PubMed
5) Iguchi Y, et al:Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan:analysis of 41,436 non-employee residents in Kurashiki-city. Circ J, 72:909-913, 2008
PubMed
6) Atarashi H, et al:Present status of anticoagulation treatment in Japanese patients with atrial fibrillation:a report from the J-RHYTHM Registry. Circ J, 75:1328-1333, 2011
 
7) Suzuki S, et al:Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo. J Cardiol, 58:116-123, 2011
 
8) Guidelines for pharmacotherapy of atrial fibrillation(JCS 2013). Circ J, 78 (8):1997-2021, 2014
PubMed
9) Steinberg BA, et al:Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation:results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation, 129:2005-2012, 2014
PubMed

第1章 はじまりは心電図

P.31 掲載の参考文献
1) Morganroth J, et al:Relationship of atrial fibrillatory wave amplitude to left atrial size and etiology of heart disease. An old generalization re-examined. Am Heart J, 97:184-186, 1979
PubMed
2) Andrade JG, et al:ECG features associated with adverse cardiovascular outcomes in patients with atrial fibrillation:a combined AFFIRM and AF-CHF analysis. J Cardiovasc Electrophysiol, 27:404-413, 2016
PubMed
P.37 掲載の参考文献
1) Akao M, et al:Current status of clinical background of patients with atrial fibrillation in a community-based survey:the Fushimi AF Registry. J Cardiol, 61:260-266, 2013
 
2) Takabayashi K, et al:Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation:the Fushimi atrial fibrillation Registry. Stroke, 46:3354-3361, 2015
 
3) Ogawa S, et al:Optimal treatment strategy for patients with paroxysmal atrial fibrillation:J-RHYTHM Study. Circ J, 73:242-248, 2009
PubMed
4) Hohnloser SH, et al:Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy:an ACTIVE W Substudy. J Am Coll Cardiol, 50:2156-2161, 2007
PubMed
5) Koga M, et al:Higher risk of ischemic events in secondary prevention for patients with persistent than those with paroxysmal atrial fibrillation. Stroke, 47:2582-2588, 2016
PubMed
6) Toyoda K, et al:Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan:the SAMURAI-NVAF study. Int J Stroke, 10:836-842, 2015
PubMed
7) 出口一郎, 他:心房細動 (発作性と持続性) における重症度, 予後等の相違. 「脳卒中データバンク 2015」(小林祥泰/編), pp58-59, 中山書店, 2015
 
8) Boriani G, et al:Device-detected atrial fibrillation and risk for stroke:an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J, 35:508-516, 2014
 

第2章 全身を評価する

P.45 掲載の参考文献
1) 平成26年高齢社会白書 (http://www8.cao.go.jp/kourei/whitepaper/index-w.html)
 
2) Yamashita Y, et al:Clinical characteristics and outcomes in extreme elderly (age >-85 years) Japanese patients with atrial fibrillation:the Fushimi AF Registry. Chest, 149:401-412, 2016
PubMed
3) Pugh D, et al:Attitudes of physicians regarding anticoagulation for atrial fibrillation:a systematic review. Age Ageing, 40:675-683, 2011
PubMed
4) Sellers MB & Newby LK:Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J, 161:241-246, 2011
PubMed
5) Donze J, et al:Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med, 125:773-778, 2012
PubMed
6) Perera V, et al:The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing, 38:156-162, 2009
PubMed
P.52 掲載の参考文献
1) Benjamin EJ, et al:Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 271:840-844, 1994
 
2) Kjeldsen SE, et al:Arterial stiffness predicts incident atrial fibrillation in the Framingham heart study:a mechanistic contribution in people with high blood pressure or history of hypertension. Hypertension, 68:555-557, 2016
PubMed
3) Kirchhof P, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
4) Julius S, et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet, 363:2022-2031, 2004
 
5) Guidelines for pharmacotherapy of atrial fibrillation(JCS 2013). Circ J, 78:1997-2021, 2014
PubMed
6) Kodani E, et al:Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation:a subanalysis of the J-RHYTHM registry. J Am Heart Assoc, 5, 2016
 
7) Ashburner JM, et al:Effect of diabetes and glycemic control on ischemic stroke risk in AF patients:ATRIA Study. J Am Coll Cardiol, 67:239-247, 2016
PubMed
8) Lip GY, et al:Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation. Chest, 137:263-272, 2010
PubMed
P.62 掲載の参考文献
1) Matsuo S, et al:Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 53:982-992, 2009
PubMed
2) Cockcroft DW & Gault MH:Prediction of creatinine clearance from serum creatinine. Nephron, 16:31-41, 1976
PubMed
3) Parsh J, et al:Choice of estimated glomerular filtration rate equation impacts drug-dosing recommendations and risk stratification in patients with chronic kidney disease undergoing percutaneous coronary interventions. J Am Coll Cardiol, 65:2714-2723, 2015
PubMed
4) Olesen JB, et al:Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med, 367:625-635, 2012
PubMed
5) Yamashita Y, et al:Clinical characteristics and outcomes of dialysis patients with atrial fibrillation:the Fushimi AF Registry. Heart Vessels, 31:2025-2034, 2016
PubMed
P.70 掲載の参考文献
1) Akao M, et al:Current status of clinical background of patients with atrial fibrillation in a community-based survey:the Fushimi AF Registry. J Cardiol, 61:260-266, 2013
 
2) Goto K, et al:Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol, 114:70-78, 2014
PubMed
3) Winkel TA, et al:Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease:data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg, 40:9-16, 2010
PubMed
4) Dewilde WJ, et al:Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label, randomised, controlled trial. Lancet, 381:1107-1115, 2013
 
5) Kirchhof P, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
6) Gibson CM, et al:Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 375:2423-2434, 2016
PubMed
7) Natsuaki M, et al:One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation:ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther, 31:196-209, 2016
PubMed
P.79 掲載の参考文献
1) Bokura H, et al:Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke, 42:1867-1871, 2011
PubMed
2) Gage BF, et al:Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation. JAMA, 285:2864-2870, 2001
 
3) Hart RG, et al:Embolic strokes of undetermined source:the case for a new clinical construct. Lancet Neurol, 13:429-438, 2014
PubMed
P.80 掲載の参考文献
1) Yasuda K, et al:Predictors of cardioembolic stroke in Japanese patients with atrial fibrillation:the Fushimi AF Registry. Asia Pacific Stroke Conference 2016, Brisbane, Queensland, Australia, 15-17 July, 2016
 
P.88 掲載の参考文献
1) Ponikowski P, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur Heart J, 37(27):2129-200, 2016
 
2)Santhanakrishnan R, et al:Atrial fibrillation begets heart failure and vice versa:temporal associations and differences in preserved versus reduced ejection fraction. Circulation, 133:484-492, 2016
PubMed
3)Healey JS, et al:Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation:a cohort study. Lancet, 388:1161-1169, 2016
PubMed
4)Potpara TS, et al:Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts:the Belgrade Atrial Fibrillation Study. Eur J Heart Fail, 15:415-424, 2013
PubMed
5)Agarwal M, et al:The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients:a systematic review. Clin Ther, 36:1135-1144, 2014
PubMed
6)Hamatani Y, et al:Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure. Heart Vessels, 31:1154-1161, 2016
PubMed
7)McMurray JJ, et al:Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation:insights from the ARISTOTLE trial. Circ Heart Fail, 6:451-460, 2013
PubMed
8)Kotecha D, et al:Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis. Lancet, 384:2235-2243, 2014
 
9)Rathore SS, et al:Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA, 289:871-878, 2003
PubMed
P.93 掲載の参考文献
1) Elliott P, et al:Classification of the cardiomyopathies:a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 29:270-276, 2008
 
2) 「循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) 肥大型心筋症の診療に関するガイドライン(2012年改訂版)」(合同研究班参加学会), 2012
 
3) Gersh BJ, et al:2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Thorac Cardiovasc Surg, 142:e153-e203, 2011
 
4) Takagi E, et al:Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol, 33:206-211, 1999
PubMed
5) Haruki S, et al:Stroke and embolic events in hypertrophic cardiomyopathy:risk stratification in patients without atrial fibrillation. Stroke, 47:936-942, 2016
PubMed
6) Olivotto I, et al:Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation, 104:2517-2524, 2001
PubMed
7) De Ferrari GM, et al:Atrial fibrillation in heart failure patients:prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail, 9:502-509, 2007
PubMed
8) Ahnert AM & Freudenberger RS:What do we know about anticoagulation in patients with heart failure? Curr Opin Cardiol, 23:228-232, 2008
PubMed
9) 「循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告) 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン」(合同研究班参加学会), 2011
 
10) Aleksova A, et al:Impact of atrial fibrillation on outcome of patients with idiopathic dilated cardiomyopathy:data from the Heart Muscle Disease Registry of Trieste. Clin Med Res, 8:142-149, 2010
PubMed
P.102 掲載の参考文献
1) Haissaguerre M, et al:Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med, 344:1043-1051, 1998
 
2) Di Biase L, et al:Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol, 60:531-538, 2012
PubMed
3) Lang RM, et al:Recommendations for cardiac chamber quantification by echocardiography in adults:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 28:1-39, 2015
PubMed
4) Zabalgoitia M, et al:Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol, 31:1622-1626, 1998
 
5) Abu-El-Haija B & Giudici MC:Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion. Clin Cardiol, 37:381-385, 2014
PubMed
6) Okishige K, et al:Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide:pilsicainide suppression trial for persistent atrial fibrillation II. Circ J, 70:657-661, 2006
PubMed
7) Shiga T, et al:Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J, 66:600-604, 2002
 
8) Hamatani Y, et al:Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep, 6:31042, 2016
PubMed
P.106 掲載の参考文献
1) Groppelli A, et al:Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition. J Hypertens Suppl, 8:S35-S40, 1990
PubMed
2) Kasza KA, et al:Effectiveness of stop-smoking medications:findings from the International Tobacco Control (ITC) Four Country Survey. Addiction, 108:193-202, 2013
PubMed
3) Higuchi S, et al:Japan:alcohol today. Addiction, 102:1849-1862, 2007
PubMed
4) Lin Y, et al:Alcohol consumption and mortality among middle-aged and elderly Japanese men and women. Ann Epidemiol, 15:590-597, 2005
PubMed
5) Criqui MH, et al:Dietary alcohol, calcium, and potassium. Independent and combined effects on blood pressure. Circulation, 80:609-614, 1989
PubMed
6) Sano F, et al:Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). Circ J, 78:955-961, 2014
PubMed

第3章 脳塞栓症を防ぐ

P.114 掲載の参考文献
1) Gage BF, et al:Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation. JAMA, 285:2864-2870, 2001
 
2) Lip GY, et al:Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation. Chest, 137:263-272, 2010
PubMed
3) Lip GY, et al:Identifying patients at high risk for stroke despite anticoagulation:a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke, 41:2731-2738, 2010
 
4) January C. T, et al:2014 AHA/ACC/HRS guideline for the management of Patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 130:e199-267, 2014
 
5) Kirchhof P, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 37:2893-2962, 2016
PubMed
6) Suzuki S, et al:Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J, 79:432-438, 2015
 
7) Pisters R, et al:A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey. Chest, 138:1093-1100, 2010
PubMed
8) Fang MC, et al:A new risk scheme to predict warfarin-associated hemorrhage:The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol, 58:395-401, 2011
PubMed
9) O'Brien, E. C, et al:The ORBIT bleeding score:a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J, 36:3258-3264, 2015
 
10) Hijazi Z, et al:The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation:a derivation and validation study. Lancet, 387:2302-2311, 2016
PubMed
P.116 掲載の参考文献
1) Inoue H, et al:Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol, 113:957-962, 2014
PubMed
2) Suzuki S, et al:Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J, 79:432-438, 2015
 
P.124 掲載の参考文献
1) Pirmohamed M, et al:A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 369:2294-2303, 2013
PubMed
2) Kimmel SE, et al:A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 369:2283-2293, 2013
PubMed
3) Foley AM:Review of article:Perioperative bridging anticoagulation in patients with atrial fibrillation by James D. Douketis, MD, Alex C. Spyropoulos, MD, Scott Kaatz, DO, et al (N Engl J Med 2015;373:823-833).
 
4) Morgan CL, et al:Warfarin treatment in patients with atrial fibrillation:observing outcomes associated with varying levels of INR control. Thromb Res, 124:37-41, 2009
PubMed
J Vasc Nurs, 33:167-168, 2015
PubMed
P.133 掲載の参考文献
1) Eikelboom JW, et al:Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med, 369:1206-1214, 2013
PubMed
2) Akao M, et al:Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J, 78:2166-2172, 2014
PubMed
3) Piccini JP, et al:Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation, 133:352-360, 2016
PubMed
4) Ruff CT, et al:Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. Lancet, 383:955-962, 2014
PubMed
5) Connolly SJ, et al:Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361:1139-1151, 2009
PubMed
6) Hori M, et al:Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study -. Circ J, 76:2104-2111, 2012
 
7) Granger CB, et al:Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 365:981-992, 2011
PubMed
8) Giugliano RP, et al:Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 369:2093-2104, 2013
PubMed
P.139 掲載の参考文献
1) Guidelines for pharmacotherapy of atrial fibrillation(JCS 2013). Circ J, 78:1997-2021, 2014
PubMed
2) Kirchhof P, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
3) Connolly S, et al:Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W):a randomised controlled trial. Lancet, 367:1903-1912, 2006
 

第4章 症状を緩和する

P.148 掲載の参考文献
1) Hunter RJ, et al:A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol, 7:31-38, 2014
PubMed
2) Yasuda M, et al:Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J, 70:662-666, 2006
PubMed
3) Verma A, et al:Approaches to catheter ablation for persistent atrial fibrillation. N Eng J Med, 372:1812-1822, 2015
 
4) Hohnloser SH, et al:Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med, 360:668-678, 2009
PubMed
5) Tsadok MA, et al:Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation, 126:2680-2687, 2012
PubMed
6) Friberg L, et al:Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death:data from Swedish health registries. Eur Heart J, 37:2478-2487, 2016
PubMed
P.150 掲載の参考文献
1) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 339:659-666, 1998
PubMed
2) Tilz RR, et al:Catheter ablation of long-standing persistent atrial fibrillation:5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol. 60:1921-1929, 2012
PubMed
P.153 掲載の参考文献
1) Cox JL, et al:The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg, 101:569-583, 1991
PubMed
2) 「循環器病の診断と治療に関するガイドライン(2010年度合同研究班報告) 不整脈の非薬物療法ガイドライン 2006年度改訂版」(合同研究班参加学会), 2011
 
3) Ohtsuka T, et al:Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. J Am Coll Cardiol, 62:103-107, 2013
PubMed
4) Masuda M, et al:Thoracic and cardiovascular surgery in Japan during 2014:Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg, 64:665-697, 2016
PubMed
5) Gillinov AM, et al:Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med, 372:1399-1409, 2015
PubMed
P.161 掲載の参考文献
1) Wyse DG, et al:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 347:1825-1833, 2002
PubMed
2) de Denus S, et al:Rate vs rhythm control in patients with atrial fibrillation:a meta-analysis. Arch Intern Med, 165:258-262, 2005
PubMed
3) Van Gelder IC, et al:Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med, 362:1363-1373, 2010
PubMed
4) Goldstein RE, et al:Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation, 83:52-60, 1991
 
5) Kotecha D, et al:Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis. Lancet, 384:2235-2243, 2014
 
6) Ziff OJ, et al:Safety and efficacy of digoxin:systematic review and meta-analysis of observational and controlled trial data. BMJ, 351:h4451, 2015
PubMed

第5章 連携して診る

P.166 掲載の参考文献
1) Wang Y, et al:Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res, 133:550-554, 2014
PubMed
2) Clarkesmith DE, et al:Educational intervention improves anticoagulation control in atrial fibrillation patients:the TREAT randomised trial. PLoS One, 8:e74037, 2013
 
3) Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
P.172 掲載の参考文献
1) Osterberg L & Blaschke T:Adherence to medication. N Engl J Med, 353:487-497, 2005
PubMed
2) Fang MC, et al:Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes, 3:624-631, 2010
PubMed
3) Parker CS, et al:Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports:results from the IN-RANGE study. J Gen Intern Med, 22:1254-1259, 2007
PubMed
4) Castellucci LA, et al:Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res, 136:727-731, 2015
PubMed
5) Shore S, et al:Adherence to dabigatran therapy and longitudinal patient outcomes:insights from the veterans health administration. Am Heart J, 167:810-817, 2014
PubMed
6) Beyer-Westendorf J, et al:Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace, 18:1150-1157, 2016
PubMed
P.190 掲載の参考文献
1) Ho PM, et al:Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge:a randomized clinical trial. JAMA Intern Med, 174:186-193, 2014
PubMed
2) Stewart RB:Polypharmacy in the elderly:a fait accompli? DICP, 24:321-323, 1990
PubMed
3) Beijer HJ & de Blaey CJ:Hospitalisations caused by adverse drug reactions (ADR):a meta-analysis of observational studies. Pharm World Sci, 24:46-54, 2002
PubMed
4) Chan M, et al:Adverse drug events as a cause of hospital admission in the elderly. Intern Med J, 31:199-205, 2001
PubMed
P.199 掲載の参考文献
1) 藤本一眞, 他:抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterol Endosc, 54:2075-2102, 2012
 
2) Acosta RD, et al:The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc, 83:3-16, 2016
PubMed
3) Veitch AM, et al:Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants:British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy, 48:385-402, 2016
 
4) Rose AJ, et al:A call to reduce the use of bridging anticoagulation. Circ Cardiovasc Qual Outcomes, 9:64-67, 2016
 
P.207 掲載の参考文献
1) 矢坂正弘, 観血的医療処置時の抗血栓薬の適切な管理に関する研究(MARK研究), 第41回日本脳卒中学会, 札幌, 2016
 
2) Heidbuchel H, et al:Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 17:1467-1507, 2015
 
3) Douketis JD, et al:Perioperative management of antithrombotic therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141:e326S-e350S, 2012
PubMed
4) Horlocker TT, et al:Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy:American Society of Regional Anesthesia and Pain Medicine EvidenceBased Guidelines (Third Edition). Reg Anesth Pain Med, 35:64-101, 2010
 
5) Gialdini G, et al:Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA, 312:616-622, 2014
 
P.208 掲載の参考文献
1) Annane D, et al:Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med, 178:20-25, 2008
PubMed
2) Kindem IA, et al:New-onset atrial fibrillation in bacteremia is not associated with C-reactive protein, but is an indicator of increased mortality during hospitalization. Cardiology, 111:171-180, 2008
PubMed
P.210 掲載の参考文献
1) Romero I, et al:Diagnosis and management of atrial fibrillation:an overview. Cardiovasc Ther, 32:242-252, 2014
PubMed
2) Mariscalco G, et al:Atrial fibrillation after isolated coronary surgery affects late survival. Circulation, 118:1612-1618, 2008
PubMed
3) Arakawa M, et al:Postoperative atrial fibrillation after thoracic aortic surgery. Ann Thorac Surg, 99:103-108, 2015
PubMed
4) LaPar DJ, et al:Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg, 98:527-33; discussion 533, 2014
PubMed
5) Wyse DG, et al:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 347:1825-1833, 2002
PubMed
6) Gillinov AM, et al:Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med, 374:1911-1921, 2016
PubMed
P.220 掲載の参考文献
1) Jauch EC, et al:Guidelines for the early management of patients with acute ischemic stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 44:870-947, 2013
PubMed
2) Lyden P, et al:Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke, 25:2220-2226, 1994
 
3) Ohtani R:虚血性脳血管障害急性期 rt-PA(アルテプラーゼ) 静注療法マニュアル 国立病院機構京都医療センター版 (http://www.hosp.go.jp/~kyotolan/img/img/guide/medicalinfo/neurology/rt-pa-1.pdf)
 
4) Hirsch JA & Gonzalez RG:Understanding IMS III:old data shed new light on a futile trial. J Neurointerv Surg, 6:3-4, 2014
 
5) Camerlingo M, et al:Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke, 36:2415-2420, 2005
PubMed
P.225 掲載の参考文献
1) Takabayashi K, et al:Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation:the Fushimi atrial fibrillation Registry. Stroke, 46:3354-3361, 2015
 
2) Hamatani Y, et al:Low body weight is associated with the incidence of stroke in atrial fibrillation patients-insight from the Fushimi AF Registry. Circ J, 79:1009-1017, 2015
PubMed

第6章 徹底討論 ! 症例カンファレンス

P.231 掲載の参考文献
1) Douketis JD, et al.:Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med, 373:823-833, 2015
PubMed
2) Douketis JD, et al:Perioperative management of antithrombotic therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141:e326S-e350S, 2012
PubMed
3) Rose AJ, et al.:A call to reduce the use of bridging anticoagulation.Circ Cardiovasc Qual Outcomes, 9:64-67, 2016
 
4) Beyer-Westendorf J, et al.:Peri-interventional management of novel oral anticoagulants in daily care:results from the prospective Dresden NOAC registry. Eur Heart J, 35:1888-1896, 2014
PubMed
P.237 掲載の参考文献
1) Roy D, et al:Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med, 358:2667-2677, 2008
PubMed
2) Di Biase L, et al:Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device:results from the AATAC multicenter randomized trial. Circulation, 133:1637-1644, 2016
 
3) Friberg L, et al:Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death:data from Swedish health registries. Eur Heart J, 37:2478-2487, 2016
PubMed
P.243 掲載の参考文献
1) Lip GY, et al:Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association(EHRA), European Association of Percutaneous Cardiovascular Interventions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS)and Asia-Pacific Heart Rhythm Society(APHRS). Eur Heart J, 35:3155-3179, 2014
 
2) Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
3) Dewilde WJ, et al:Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label, randomised, controlled trial. Lancet, 381:1107-1115, 2013
 
4) Held C, et al:Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin:insights from the ARISTOTLE trial. Eur Heart J, 36:1264-1272, 2015
 
P.249 掲載の参考文献
1) Piccini JP, et al:Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation, 133:352-360, 2016
PubMed
2) Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37:2893-2962, 2016
PubMed
3) Reddy VY, et al:Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation:a randomized clinical trial. JAMA, 312:1988-1998, 2014
PubMed
4) Ohtsuka T, et al:Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. J Am Coll Cardiol, 62:103-107, 2013
PubMed
5) Noelck N, et al:Effectiveness of left atrial appendage exclusion procedures to reduce the risk of stroke:A systematic review of the evidence. Circ Cardiovasc Qual Outcomes, 9:395-405, 2016
PubMed
6) Kim JS, et al:Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry. Circ J, 80:1123-1130, 2016
 

書評

最近チェックした商品履歴

Loading...